Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Enrico M. Novelli, MD
Healthcare Provider Associate Professor of Medicine
Vascular Medicine Institute
E1257 BST
200 Lothrop Street
Pittsburgh, Pennsylvania, United States
Dr. Novelli obtained his MD degree from the University of Milan, Italy in 1996. He was a postdoctoral fellow at Johns Hopkins University from 1996 to 1999 where he developed expertise in cellular biology and gene therapy. Dr. Novelli’s main areas of interest are sickle cell disease and disorders of hemostasis. Dr. Novelli holds a sickle cell disease and hemoglobinopathy clinic at the Hillman Cancer Center and a hemophilia and thrombosis clinic at the Hemophilia Center of Western Pennsylvania. In addition, he works as a member of the inpatient hematology consult service for several weeks of the year. Another longstanding interest of Dr. Novelli’s is in developing global health research and training initiatives in Tropical Hematology.
Research Interests: One recent interest of Dr. Novelli’s is elucidating the fundamental mechanisms underlying hemolysis-associated thrombosis and vascular dysfunction in SCD. Patients with SCD suffer from severe chronic hemolytic anemia and acute episodes of RBC trapping and destruction in the microvasculature (vaso-occlusive crises). Dr. Novelli’s current research project explores the role of Thrombospondin-1 (TSP1), a glycoprotein abundantly present in platelet α-granules which is emerging as a key regulator of hemostasis and thrombosis.
Representative Publications:
Pulmonary embolism in sickle cell disease: a case-control study
Related Content
-
Betty Pace, MDDr. Betty Pace is a pediatric hematologi...
-
Kathryn E Scott, MDDr. Scott is affiliated with General Ped...
-
International Association of Sickle Cell Nurses and Professional AssociatesThe International Association of Sickle ...
-
Prodigy’s death shines light on slow progress against sickle cell diseaseThe death of the rap artist Prodigy (Alb...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
University of Pittsburgh School of MedicineThe University of Pittsburgh School of M...
-
Pharmacogenetics for Safe Codeine Use in Sickle Cell DiseaseAfter postoperative deaths in children w...